New Preorder Patent Owner Rights in Ex Parte Reexamination — Patents: Post-Grant Podcast
At the Intersection of Biotech and AI with Janice Vatland
Protecting Your Products and Brand Online
IP Goes Pop! S7 Ep 1- We’re #1! Intellectual Property Firsts
Michele Moresco on the Transformational Potential of Photonics
AI in Biotech: What Does it Mean for Life Sciences Innovation?
The Briefing: 2025 IP Resolutions Start With a Review of IP Assets (Featured)
The Briefing: A Very Patented Christmas – The Quirkiest Inventions for the Holiday Season (Featured)
(Podcast) The Briefing: A Very Patented Christmas – The Quirkiest Inventions for the Holiday Season (Featured)
Practical IP Lessons From the Field: Field Trials, Trade Secrets, and the Hydrogen Horizon - Energy Law Insights
Practical IP Lessons From the Field Part Two: Navigating IP Risk in Oil & Gas - Energy Law Insights
Practical IP Lessons From the Field Part One: Protecting Innovation in Oil & Gas - Energy Law Insights
AI Today in 5: October 27, 2025, The Trusting Your Eyes Edition
It Only Took 13 Years: The Federal Circuit's First Derivation Proceeding Decision — Patents: Post-Grant Podcast
PODCAST: Williams Mullen's Trending Now: An IP Podcast - Who Owns AI Innovation? IP in the Age of Artificial Intelligence
Money-Saving Licensing Tips for Startups
Understanding the Impact of IPR Estoppel and PTAB Discretionary Denials — Patents: Post-Grant Podcast
5 Key Takeaways | Making Sense of §102 Public Use and On Sale Bars to Patentability
Unexpected Paths to IP Law with Dan Young and Colin White
Navigating PTAB’s New Approach to IPR and PGR Discretionary Denial - Patents: Post-Grant Podcast
Addressing patent eligibility and attorneys’ fees, the US Court of Appeals for the Federal Circuit affirmed a district court’s ruling that five farming data patents were directed to patent-ineligible subject matter, but...more
In most commercially significant inventions, strategic filing of various types of “child” patent applications (patent applications extending from an original or “parent” patent application) in various worldwide jurisdictions...more
On June 4, 2026, a unanimous Supreme Court in Hikma Pharms. USA Inc. v. Amarin Pharma, Inc., No. 24-889, clarified the standard for pleading induced patent infringement under 35 U.S.C. § 271(b). ...more
On June 8, Alvotech announced that the U.S. Food and Drug Administration (“FDA”) has accepted Alvotech’s Biologics License Application (“BLA”) for AVT16, a proposed interchangeable biosimilar to Takeda’s ENTYVIO...more
On June 4, 2026 in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the U.S. Supreme Court issued a unanimous decision that materially recalibrates inducement analysis in the context of Section viii carve-outs....more
Background - In a precedential Director discretionary denial issued May 14, 2026, USPTO Director John A. Squires denied institution of inter partes review in Magnolia Medical Technologies, Inc. v. Kurin, Inc., holding that...more
Despite periodic mentions by aerospace innovators of “secret patents,” this author is not aware of any evidence of such patents. There may be confusion with “Secrecy Orders,” which apply to patent applications, but not to...more
In Ollnova Technologies Ltd. v. ecobee Technologies ULC, the Federal Circuit handed Ollnova a string of doctrinal wins — three of its four patents cleared the patent eligibility hurdle under 35 U.S.C. § 101 — only to throw...more
The U.S. Supreme Court has now issued its decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., unanimously reversing the Federal Circuit and narrowing the circumstances in which generic drug manufacturers may...more
Patent enforcement has always required two decisions, not one. The first is the obvious question: can the patent owner prove infringement and survive the expected validity challenges? The second is the question that...more
Investment Committee Takeaways - Agentic AI is changing diligence from a fixed workstream into a continuously operating risk engine. The core question is no longer whether a portfolio looks strong; it is whether the portfolio...more
On October 17, 2025, USPTO Director John Squires issued a memorandum announcing that he would be sole decision-maker for institution of inter partes review (IPR) and post-grant review (PGR) proceedings....more
In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (June 4, 2026), a unanimous Supreme Court has further clarified what it takes to plead — and ultimately prove — that a defendant induced another party to infringe a...more
The Supreme Court unanimously ruled in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., No. 24-889, that a branded pharmaceutical company alleging induced patent infringement against a generic manufacturer must plausibly...more
The Federal Circuit’s new precedential decision in Ollnova Technologies Ltd. v. ecobee Technologies ULC may have significant implications for how patent cases are tried, particularly in multi-patent disputes involving...more
On May 4, 2026, the United States Court of Appeals for the Federal Circuit (Judges Lourie, Prost, and District Judge Burroughs) affirmed a decision of the United States District Court for the Eastern District of Arkansas...more
On June 4, 2026, Justice Ketanji Brown Jackson, writing for a unanimous Supreme Court of the United States, reversed a decision by the United States Court of Appeals for the Federal Circuit and held that Amarin Pharma, Inc....more
Hikma Pharms USA Inc. v. Amarin Pharma, Inc., Appeal No. 24-889 (Sup. Ct. June 4, 2026) - In its first patent case of 2026, the Supreme Court addressed a question of induced infringement as applied to the pharmaceutical...more
The UPC Court of Appeal has delivered an important ruling in Fujifilm v Kodak, confirming that the Unified Patent Court’s jurisdiction may extend to non-UPC European patent designations. The decision distinguishes between the...more
By now most people have heard that Hikma v. Amarin, No. 24–889 (June 4, 2026), was an overall favorable decision for skinny labeling. But what are the practical takeaways? Here we outline the facts and factors considered by...more
Key Takeaways: In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, the Supreme Court reversed the Federal Circuit and held that a generic drug manufacturer’s FDA-compliant skinny label, combined with...more
On June 4, 2026, the United States Supreme Court issued its decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. In its decision, the Supreme Court reversed the Federal Circuit, and held that Amarin’s complaint...more
The Senate passed the reconciliation 2.0 package, which funds ICE and CBP and includes no healthcare provisions. The bill now moves to the House, though Republican leadership cancelled Friday votes, postponing further action...more
Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR, claims are counted only once, whether they...more
Etanercept Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more